Nektar Therapeutics
NKTR
249 hedge funds and large institutions have $2.88B invested in Nektar Therapeutics in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 65 increasing their positions, 108 reducing their positions, and 32 closing their positions.
36% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $10.9M
1.43% less ownership
Funds ownership: 98.35% → 96.91% (-1.4%)
4% less funds holding
Funds holding: 260 → 249 (-11)
29% less capital invested
Capital invested by funds: $4.05B → $2.88B (-$1.18B)
31% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 32
40% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 108
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$52.6M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$10.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.92M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$4.4M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$15.3M |
| 2 |
BlackRock
New York
|
-$14.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$14M |
| 4 |
Primecap Management
Pasadena,
California
|
-$11.3M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$10.5M |
NKTR Hedge Fund Activity: Q3 2020 in Review
249 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2020, worth a combined $2.88B — down 29% from $4.05B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of NKTR and 22 opened new positions — a net loss of 10 holders — while 108 trimmed existing stakes and 65 added.
The largest buyer was Invesco, adding an estimated $52.6M. The largest seller was Goldman Sachs, cutting an estimated $15.3M.
- 249 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2020, down from 260 in Q2 2020.
- Funds reported $2.88B of Nektar Therapeutics stock for Q3 2020, down 29% quarter-over-quarter.
- 22 funds opened new Nektar Therapeutics positions in Q3 2020 and 32 closed out, a net change of -10 holders.
- The largest Nektar Therapeutics buyer in Q3 2020 was Invesco, an estimated $52.6M added.
- The largest Nektar Therapeutics seller in Q3 2020 was Goldman Sachs, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2020.